Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.54 |
| ▸ | HTR3A | P46098 | 12/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4702540 | 0.92 | HTR1A (0.50) | HTR1AHTR3ADRD2CYP1A2CYP3A4 | |
| SCHEMBL4700194 | 0.87 | HTR1A (0.55) | HTR1AHTR3ADRD2CYP1A2CYP3A4 | |
| SCHEMBL4703103 | 0.85 | HTR1A (0.57) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4702499 | 0.85 | DRD2 (0.47) | HTR1AHTR3ADRD2CYP1A2CYP3A4 | |
| SCHEMBL4698313 | 0.81 | DRD2 (0.43) | HTR1AHTR3ADRD2CYP1A2CYP3A4 | |
| SCHEMBL4702827 | 0.81 | DRD2 (0.51) | HTR1AHTR3ADRD2CYP1A2CYP3A4 | |
| SCHEMBL4701018 | 0.81 | HTR1A (0.50) | HTR1AHTR3ADRD2CYP1A2CYP3A4 | |
| SCHEMBL4701297 | 0.79 | HTR1A (0.41) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4701338 | 0.77 | DRD2 (0.47) | HTR1AHTR3ADRD2CYP1A2CYP3A4 | |
| SCHEMBL4704131 | 0.76 | HTR1A (0.42) | HTR1AHTR3ADRD2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100384822-C | 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors | LUNDBECK & CO AS H (DK) | 2008-04-30 | — | — | CN | disclosed |
| EP-1613594-B1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | LUNDBECK & CO AS H (DK) | 2008-03-26 | — | — | EP | disclosed |
| US-20070173522-A1 | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2007-07-26 | — | — | US | disclosed |
| EP-1613594-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087662-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173522-A1 | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | TPH1, HTR2C, HTR1D | HTR1A 4/4885HTR3A 11/4885DRD2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.